ReviewThe Journal of antimicrobial chemotherapy2021
A review of remdesivir for COVID-19 in pregnancy and lactation.
Review in The Journal of antimicrobial chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Safety and efficacy of major antiviral and immune therapies in pregnancy for maternal viral infections: evidence synthesis of maternal and neonatal outcomes.Frontiers in medicine · 2026Pooled it
- Remdesivir Use During Pregnancy: Findings From the Prospective COVID-19 International Drug Pregnancy Registry and Narrative Literature Review.Journal of pregnancy · 2026Review
- Severe COVID-19 in pregnancy: evaluation of ventilatory outcomes on a 101-cases cohort.Revista do Instituto de Medicina Tropical de Sao Paulo · 2025Article
- Trying to get breastfeeding women out of the pharmaceutical orphanage.Pediatric research · 2024Article
- Remdesivir: treatment of COVID-19 in special populations.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Detection of potential safety signals related to the use of remdesivir and tocilizumab in the COVID era during pregnancy, resorting to open data from the FDA adverse event reporting system (FAERS).Frontiers in pharmacology · 2024Article
- Article
- Is it possible to reduce the rate of vertical transmission and improve perinatal outcomes by inclusion of remdesivir in treatment regimen of pregnant women with COVID-19?BMC pregnancy and childbirth · 2023Article
- Developmental toxicity of remdesivir, an anti-COVID-19 drug, is implicated by in vitro assays using morphogenetic embryoid bodies of mouse and human pluripotent stem cells.Birth defects research · 2023Article
- European society of clinical microbiology and infectious diseases guidelines for coronavirus disease 2019: an update on treatment of patients with mild/moderate disease.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022Article
- COVID-19 critical illness in pregnancy.Obstetric medicine · 2022Review
- COVID-19: Consequences on pregnant women and neonates.Health sciences review (Oxford, England) · 2022Review
- Call for a unified approach to Monkeypox infection in pregnancy: Lessons from the COVID-19 pandemic.Nature communications · 2022Article
- Remdesivir impairs mouse preimplantation embryo development at therapeutic concentrations.Reproductive toxicology (Elmsford, N.Y.) · 2022Article
- Severe SARS-CoV-2 infection in a 32-week pregnant woman treated with Remdesivir-Dexamethasone combination therapy: A case report.Clinical case reports · 2022Article
- COVID-19 pharmacotherapy utilization patterns during pregnancy: International Registry of Coronavirus Exposure in Pregnancy.Pharmacoepidemiology and drug safety · 2022Observational
- Biotransformation and transplacental transfer of the anti-viral remdesivir and predominant metabolite, GS-441524 in pregnant rats.EBioMedicine · 2022Article
- Countering COVID-19 Vaccine Hesitancy in Pregnancy: the "4 Cs".American journal of perinatology · 2022Article
- RAGE against the Machine: Can Increasing Our Understanding of RAGE Help Us to Battle SARS-CoV-2 Infection in Pregnancy?International journal of molecular sciences · 2022Review
- Managing COVID-19 in pregnant women.Breathe (Sheffield, England) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mounting evidence suggests that pregnant people have an elevated risk of severe COVID-19-related complications compared with their non-pregnant counterparts, underscoring the need for effective prevention and treatment strategies. However, despite progress in innovative and flexible trial designs during the COVID-19 pandemic, regressive policies excluding pregnant and breastfeeding people from biomedical research persist. Remdesivir, a broad-spectrum antiviral, was the first drug licensed for the treatment of COVID-19, based on data showing it reduced the time to recovery in hospitalized patients. Pregnant and breastfeeding people were specifically excluded from all clinical trials of remdesivir in COVID-19, but data are accumulating from post-marketing registries, compassionate use programmes and case series/reports. In this review we synthesize these data and highlight key knowledge gaps to help inform clinical decision-making about its use in pregnancy and lactation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.